HULL HANS (Chief Business Officer) received a stock award from PLIANT THERAPEUTICS, INC.
Compensation award — not an open‑market transaction. Less informative as a directional signal.
A · 1 award
Filed: 1/27/2023ACC: 0001140361-23-003180
Officer· Chief Business Officer
Since Jun 2020
+130.20K
Net shares
Net buyer
$0.00
Total acquired
0
Open market trades
0B · 0S
2
Total transactions
130.20K acquired
Non-Derivative Transactions1
Common Stock
Direct
Shares
+54K
Price / share
—
Trade value
—
% of position
39.1%
1/25/2023
138.19K→192.19K
Total
Net shares
+54K
Net value
$0.00
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 1/25/2023 | A · Award | +54K | — | — | 39.1% | 138.19K | 192.19K |
| Total | +54K | $0.00 | ||||||
Derivative Transactions1
Stock Option (right to buy)
Direct
Converts to
Common Stock
76.20K shares
Shares
+76.20K
Strike price
34.65
Held after
76.20K
Exercisable
—
1/25/2023
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) Direct | Common Stock76.20K shares | 1/25/2023 | A · Award | +76.20K | 34.65 | — | 76.20K |
Non-Derivative Holdings (Post-Transaction)3
Common Stock
IndirectShares owned3.82K
Common Stock
IndirectShares owned13.98K
Common Stock
IndirectShares owned13.98K
Total
31.79K indirect31.79K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 3.82K | Indirect |
| Common Stock | 13.98K | Indirect |
| Common Stock | 13.98K | Indirect |
| Total | 31.79K | 31.79K indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported